LENZ Therapeutics, Inc. financial data

Symbol
LENZ on Nasdaq
Location
201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.82K % +38.6%
Debt-to-equity 6.05 % -45.7%
Return On Equity -29.6 % +37.5%
Return On Assets -27.9 % +18.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.3M shares +13.8%
Common Stock, Shares, Outstanding 28.6M shares +4.03%
Entity Public Float 363M USD +140%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 28.5M shares +5.04%
Weighted Average Number of Shares Outstanding, Diluted 28.5M shares +5.04%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.5M USD -43.6%
General and Administrative Expense 41M USD +24.7%
Operating Income (Loss) -67.9M USD +0.69%
Nonoperating Income (Expense) 9.52M USD +28.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.7M USD -63.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -58.9M USD +3.17%
Earnings Per Share, Basic 0 USD/shares -55.3%
Earnings Per Share, Diluted 0 USD/shares -55.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.4M USD -38.1%
Cash, Cash Equivalents, and Short-term Investments 202M USD -6.91%
Inventory, Net 949K USD
Assets, Current 207M USD -6.21%
Property, Plant and Equipment, Net 1.26M USD +238%
Operating Lease, Right-of-Use Asset 847K USD -44.7%
Other Assets, Noncurrent 1.6M USD +14.6%
Assets 211M USD -5.94%
Accounts Payable, Current 4.32M USD +56.5%
Employee-related Liabilities, Current 4.74M USD +116%
Accrued Liabilities, Current 12M USD +142%
Liabilities, Current 16.3M USD +112%
Operating Lease, Liability, Noncurrent 461K USD -51.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 16.8M USD +92.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 227K USD -56.6%
Retained Earnings (Accumulated Deficit) -191M USD -44.5%
Stockholders' Equity Attributable to Parent 194M USD -9.92%
Liabilities and Equity 211M USD -5.94%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16M USD +33%
Net Cash Provided by (Used in) Financing Activities 171M USD +106%
Net Cash Provided by (Used in) Investing Activities 18.9M USD +4.94%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 28.6M shares +3.96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.88M USD -98.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.4M USD -38.3%
Deferred Tax Assets, Valuation Allowance 53.2M USD +98.9%
Deferred Tax Assets, Gross 53.8M USD +101%
Operating Lease, Liability 954K USD -33.4%
Depreciation 2.4M USD 0%
Payments to Acquire Property, Plant, and Equipment 110K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -59.2M USD +1.83%
Lessee, Operating Lease, Liability, to be Paid 1.03M USD -35.7%
Property, Plant and Equipment, Gross 719K USD +788%
Operating Lease, Liability, Current 493K USD -21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 511K USD -11.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 157K USD +3.97%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 75K USD -55.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 361K USD -29.4%
Deferred Tax Assets, Operating Loss Carryforwards 15.5M USD +291%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.28M USD +119%
Lessee, Operating Lease, Liability, to be Paid, Year Four 361K USD -95.7%
Operating Lease, Payments 1.75M USD +32.5%
Additional Paid in Capital 385M USD +10.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 36K USD +620%
Deferred Tax Assets, Net of Valuation Allowance 620K USD +738%
Share-based Payment Arrangement, Expense 10.5M USD +99.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%